Raptor Pharmaceutical Corp. (NASDAQ:RPTP):
The company’s RSI reading has hit 62.19. The stock edged higher by 7.10% to close previous trading session at USD 4.45.
The shares of the company fluctuated in the range of USD 2.94 and USD 16.28 in the course of 52 weeks. Over the three months, the company’s shares have declined by -13.26% and in the past one year, it has lost -62.48%. Additionally, the stock’s year to date performance has declined -14.42%. Over the last five days its shares have surged by 6.46% and in the past six months it has moved down -36.52%.
Further, the company is trading at a price to book ratio of 3.22. The stock’s weekly volatility is calculated as 10.66% and monthly volatility as 9.17% with ATR of 0.35, beta of 0.83 and price to cash ratio of 2.41.
Raptor Pharmaceutical Corp. (RPTP) on March 21, 2016 announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.
PDL BioPharma Inc (NASDAQ:PDLI):
The stock increased by 6.96% to close last trading session at USD 3.38. The company’s shares oscillated in the range of USD 3.15 and USD 3.42 during intraday trade.
A total of 2.66 million shares exchanged hands, below its 3 month average volume of 2.99 million shares. Over the last five days its shares have surged by 4.32% and in the past six months it has moved down -32.26%.
Furthermore, the stock has weekly volatility of 7.12% and monthly volatility of 7.19% with ATR of 0.20. The stock’s RSI is 59.59 and distance from 50-day simple moving average is 11.00%, whereas its distance from 20-day simple moving average is 8.48% and distance from 200-day simple moving average is -22.36%.
PDL BioPharma Inc (PDLI) announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of March 4, 2016, the record date.
PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has committed over $1 billion and funded approximately $937 million in these investments to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on acquiring new income generating assets, the management of its intellectual property and income generating assets, and maximizing value for its shareholders.